Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $19.67 Average PT from Brokerages

Teva Pharmaceutical Industries Limited (NYSE:TEVA) has received an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $19.67.

Several research firms have commented on TEVA. UBS Group increased their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Barclays increased their price target on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, October 23rd. JPMorgan Chase & Co. increased their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Finally, Argus raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research report on Wednesday, July 10th.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Hedge funds have recently modified their holdings of the stock. New Covenant Trust Company N.A. acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at about $28,000. EntryPoint Capital LLC acquired a new position in Teva Pharmaceutical Industries in the 1st quarter worth approximately $30,000. UMB Bank n.a. increased its holdings in Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after buying an additional 2,067 shares during the period. Claro Advisors LLC acquired a new position in Teva Pharmaceutical Industries in the 3rd quarter worth approximately $52,000. Finally, Beach Investment Counsel Inc. PA acquired a new position in Teva Pharmaceutical Industries in the 2nd quarter worth approximately $48,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Up 0.7 %

NYSE:TEVA opened at $18.78 on Wednesday. Teva Pharmaceutical Industries has a 1-year low of $8.55 and a 1-year high of $19.08. The company has a 50-day moving average of $18.03 and a 200 day moving average of $17.06. The firm has a market cap of $21.27 billion, a PE ratio of -48.14, a price-to-earnings-growth ratio of 1.33 and a beta of 0.87. The company has a debt-to-equity ratio of 2.52, a current ratio of 0.89 and a quick ratio of 0.59.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.